Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience☆☆This study was sponsored by Procter & Gamble Pharmaceuticals, Cincinnati, Ohio, and Aventis Pharma, Bridgewater, New Jersey.

Harris, 1999, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis; a randomized controlled trial, J Am Med Assoc, 282, 1344, 10.1001/jama.282.14.1344 Reginster, 2000, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis, Osteoporos Int, 11, 83, 10.1007/s001980050010 McClung, 2001, Effect of risedronate on the risk of hip fracture in elderly women, N Engl J Med, 344, 333, 10.1056/NEJM200102013440503 Heaney, 2002, Risedronate reduces the risk of first vertebral fracture in osteoporotic women, Osteoporos Int, 13, 501, 10.1007/s001980200061 Cummings, 1998, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial, J Am Med Assoc, 280, 2077, 10.1001/jama.280.24.2077 Miller, 1997, Cyclical etidronate in the treatment of postmenopausal osteoporosis, Am J Med, 103, 468, 10.1016/S0002-9343(97)00278-7 Ott, 2001, Fractures, after long-term alendronate therapy, J Clin Endocrinol Metab, 86, 1835, 10.1210/jc.86.4.1835 Tonino, 2000, Skeletal benefits of alendronate, J Clin Endocrinol Metab, 85, 3109, 10.1210/jc.85.9.3109 Eastell, 2000, The effects of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis, J Bone Miner Res, 15, S229 Chesnut, 2000, A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis, Am J Med, 109, 267, 10.1016/S0002-9343(00)00490-3